Your browser is no longer supported. Please, upgrade your browser.
JAGX Jaguar Health, Inc. daily Stock Chart
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-161.25 Insider Own13.23% Shs Outstand6.09M Perf Week8.27%
Market Cap8.77M Forward P/E- EPS next Y-0.38 Insider Trans31.58% Shs Float0.84M Perf Month12.50%
Income-34.80M PEG- EPS next Q-1.27 Inst Own1.60% Short Float23.85% Perf Quarter-69.30%
Sales5.20M P/S1.69 EPS this Y71.10% Inst Trans-6.70% Short Ratio0.21 Perf Half Y-93.82%
Book/sh13.77 P/B0.10 EPS next Y93.50% ROA-79.90% Target Price7.50 Perf Year-96.36%
Cash/sh0.43 P/C3.37 EPS next 5Y40.00% ROE-380.60% 52W Range1.00 - 175.00 Perf YTD-91.01%
Dividend- P/FCF- EPS past 5Y-8.90% ROI-145.90% 52W High-99.18% Beta0.83
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin39.10% 52W Low44.00% ATR0.16
Employees17 Current Ratio0.30 Sales Q/Q100.00% Oper. Margin- RSI (14)55.35 Volatility12.14% 9.19%
OptionableNo Debt/Eq1.82 EPS Q/Q54.90% Profit Margin- Rel Volume0.55 Prev Close1.41
ShortableYes LT Debt/Eq0.00 EarningsAug 19 Payout- Avg Volume969.43K Price1.44
Recom1.50 SMA2016.58% SMA50-10.06% SMA200-87.81% Volume533,708 Change2.13%
Jul-11-17Initiated Rodman & Renshaw Buy $2
Sep-19-19 08:30AM  Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York ACCESSWIRE
Sep-18-19 08:30AM  Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer ACCESSWIRE -8.18%
Sep-16-19 08:30AM  Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico ACCESSWIRE +7.52%
Sep-09-19 08:30AM  Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel ACCESSWIRE
Aug-26-19 08:30AM  Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs ACCESSWIRE
Aug-22-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern ACCESSWIRE -7.81%
Aug-20-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director ACCESSWIRE
Aug-19-19 04:58PM  Stock Market Today: Baidu and Sina Lead a Recovery of Chinese Stocks InvestorPlace
12:40PM  A Look At Benzinga Pro's Most-Searched Tickers For August 19, 2019 Benzinga
08:30AM  Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy ACCESSWIRE
Aug-16-19 08:30AM  Jaguar Health Appoints Carol Lizak Chief Accounting Officer ACCESSWIRE -8.26%
Aug-15-19 08:55AM  Read This Before Selling Jaguar Health, Inc. (NASDAQ:JAGX) Shares Simply Wall St. -20.39%
Aug-14-19 05:15PM  Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results ACCESSWIRE
Aug-07-19 08:30AM  Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Website ACCESSWIRE
Aug-02-19 08:30AM  Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea ACCESSWIRE
Jul-26-19 12:00PM  Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today ACCESSWIRE
Jul-23-19 04:05PM  Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option ACCESSWIRE -9.90%
Jul-18-19 08:30AM  Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering ACCESSWIRE -7.17%
Jul-15-19 08:00AM  Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE -11.88%
Jul-11-19 09:00AM  Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea ACCESSWIRE
Jun-28-19 08:00AM  Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million ACCESSWIRE
Jun-26-19 08:00AM  Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome ACCESSWIRE
Jun-25-19 07:15AM  The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Benzinga +8.77%
Jun-24-19 08:00PM  Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards ACCESSWIRE
Jun-19-19 08:00AM  Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE -7.30%
Jun-18-19 08:00AM  Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors ACCESSWIRE
Jun-11-19 08:00AM  Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication ACCESSWIRE +35.92%
Jun-06-19 08:00AM  Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split ACCESSWIRE -20.98%
Jun-05-19 08:00AM  Jaguar Health CEO and Board Members Invest in Bridge Financing ACCESSWIRE -5.20%
Jun-03-19 08:00AM  Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 ACCESSWIRE
May-29-19 08:00AM  Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet ACCESSWIRE
May-24-19 04:15PM  Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders ACCESSWIRE
08:30AM  Jaguar Health, Inc. Reports 2019 First Quarter Financial Results ACCESSWIRE
Apr-25-19 08:00AM  Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief ACCESSWIRE
Apr-10-19 09:22AM  Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results ACCESSWIRE -7.85%
Apr-02-19 06:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi ACCESSWIRE -5.65%
Apr-01-19 08:05AM  Jaguar Health, Pipeline Review and Progress ACCESSWIRE +10.91%
Mar-28-19 06:00AM  Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi ACCESSWIRE
Mar-27-19 02:35PM  Four Biotech Stocks Setting The Standard On Wednesday ACCESSWIRE +15.38%
Mar-20-19 06:30AM  Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE -8.77%
Mar-18-19 02:00PM  Four Healthcare Stocks Heating Up On Monday ACCESSWIRE +192.64%
Mar-05-19 09:00AM  Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders ACCESSWIRE
Feb-25-19 12:00PM  Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019 ACCESSWIRE
Feb-21-19 02:09PM  What Kind Of Shareholders Own Jaguar Health, Inc. (NASDAQ:JAGX)? Simply Wall St.
Jan-24-19 09:00AM  With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product ACCESSWIRE
Jan-22-19 09:00AM  Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale ACCESSWIRE -8.15%
Jan-09-19 08:00AM  Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes ACCESSWIRE
Jan-07-19 08:00AM  Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates ACCESSWIRE +15.85%
Jan-03-19 08:00AM  Jaguar Health to Present at Biotech Showcase 2019 in San Francisco ACCESSWIRE +11.04%
Jan-02-19 08:00AM  Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance ACCESSWIRE +18.01%
Dec-06-18 08:00AM  Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer ACCESSWIRE -14.23%
Nov-14-18 08:05PM  Jaguar Health, Inc. Reports Third-Quarter 2018 Results ACCESSWIRE
Nov-13-18 08:00AM  Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th ACCESSWIRE
Oct-29-18 09:00AM  The Brilliance Behind a Global Operator of Crypto Exchanges BitMax: Understanding the Trans-Fee Mining Model ACCESSWIRE
09:00AM  Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th ACCESSWIRE
Oct-24-18 09:00AM  Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida ACCESSWIRE -9.86%
Oct-18-18 09:25AM  Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Oct-02-18 06:00AM  Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering ACCESSWIRE -24.18%
Sep-26-18 10:30AM  These Biotech and Cannabis Stocks Are Skyrocketing ACCESSWIRE -36.90%
08:00AM  Today's Research Reports on Trending Tickers: Jaguar Health and TG Therapeutics ACCESSWIRE
Sep-25-18 02:40PM  Jaguar Health's stock triples after licensing deal, has been halted 13 times for volatility MarketWatch +158.46%
Sep-24-18 04:36PM  Knight Therapeutics and Jaguar Health Announce Strategic Partnership GlobeNewswire
04:30PM  Knight Therapeutics and Jaguar Health Announce Strategic Partnership ACCESSWIRE
Aug-27-18 07:55AM  Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jul-25-18 08:00AM  RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi® GlobeNewswire
Jul-24-18 09:00AM  New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time ACCESSWIRE
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE -6.78%
Jul-16-18 09:00AM  Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference ACCESSWIRE -10.95%
Jul-12-18 09:00AM  Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates ACCESSWIRE +8.82%
Jun-28-18 09:00AM  RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi® GlobeNewswire +5.00%
09:00AM  Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product ACCESSWIRE
Jun-25-18 07:45AM  Research Report Identifies Glu Mobile, Reliance Steel & Aluminum, FedEx, Jaguar Animal Health, Box, and VirnetX Holding with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -8.81%
Jun-20-18 09:00AM  Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors ACCESSWIRE
Jun-18-18 09:00AM  Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors ACCESSWIRE
Jun-15-18 07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-12-18 09:00AM  Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients ACCESSWIRE
Jun-04-18 08:10AM  Today's Research Reports on Stocks to Watch: Co-Diagnostics and Jaguar Health ACCESSWIRE +9.56%
Jun-03-18 08:34AM  Is Jaguar Health Incs (NASDAQ:JAGX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Jun-01-18 09:00AM  Jaguar Health, Inc. Announces 1-for-15 Reverse Stock Split ACCESSWIRE -8.84%
May-29-18 09:00AM  Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals ACCESSWIRE
May-18-18 05:24PM  Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders ACCESSWIRE
May-15-18 11:15AM  Jaguar Health Inc (NASDAQ:JAGX): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
09:00AM  ''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea ACCESSWIRE
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-07-18 08:15AM  Research Report Identifies Jaguar Animal Health, Dollar Tree, WPX Energy, Abaxis, Lear, and Baker Hughes with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-19-18 09:00AM  Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea ACCESSWIRE
Apr-10-18 09:00AM  Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi ACCESSWIRE +6.97%
Apr-09-18 09:00AM  Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV ACCESSWIRE
Apr-02-18 09:00AM  Jaguar Health Appoints Jonathan B. Siegel to Board of Directors ACCESSWIRE
Mar-26-18 06:30AM  Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi ACCESSWIRE
Mar-13-18 07:02PM  Why Jaguar Health Incs (NASDAQ:JAGX) CEO Pay Matters To You Simply Wall St. -9.32%
03:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc. Business Wire
08:05AM  Jaguar Health, Pipeline Review, Analyst Ratings, Milestones ACCESSWIRE
Mar-09-18 08:10AM  Todays Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health ACCESSWIRE -31.05%
Mar-08-18 09:00AM  FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE +131.00%
Mar-05-18 08:10AM  Report: Developing Opportunities within TripAdvisor, Glu Mobile, KeyCorp, SMART SAND INC, Jaguar Animal Health, and Cleveland-Cliffs Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-02-18 09:00AM  Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program ACCESSWIRE
Mar-01-18 01:23PM  How Financially Strong Is Jaguar Health Inc (NASDAQ:JAGX)? Simply Wall St.
Jan-22-18 04:00PM  Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (AugustDecember 2017) Business Wire
Jan-18-18 09:00AM  Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results Business Wire +21.13%
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Siegel Jonathan B.DirectorJul 23Buy2.0012,70525,41013,276Jul 25 04:09 PM
BOCHNOWSKI JAMES JDirectorJul 23Buy2.00180,582361,164181,618Jul 25 04:08 PM
Siegel Jonathan B.DirectorOct 04Buy0.6025,00015,00040,000Oct 05 04:39 PM
Nantucket Investments Ltd10% OwnerSep 25Sale1.83325,615595,8750Oct 24 09:43 AM